What is the story about?
What's Happening?
CN Bio has announced the launch of PhysioMimix Core, an advanced Organ-on-a-chip (OOC) system designed to streamline drug discovery and development processes. This new system integrates single-organ, multi-organ, and higher-throughput configurations into one scalable platform, offering researchers a comprehensive tool for in vitro human physiology modeling. The PhysioMimix Core is compatible with existing PhysioMimix accessories and validated protocols, ensuring seamless workflow integration. The system is optimized for simplicity and functionality, featuring tubeless microfluidic engineering to minimize contamination risks and reduce maintenance needs. It supports high throughput screens of up to 288 samples simultaneously, with recirculating media and adjustable flow rates to maintain biomarker levels for long-term studies. The launch comes amid legislative changes favoring new approach methodologies (NAMs) in drug development, allowing developers to choose effective tools for advancing research.
Why It's Important?
The introduction of PhysioMimix Core represents a significant advancement in the field of drug development, providing researchers with a versatile and efficient tool to model human physiology. This system reduces reliance on animal models, aligning with the U.S. FDA's recognition of OOC technology. By offering a unified platform, CN Bio addresses a market gap, enabling drug developers to streamline their processes and enhance data translatability. The system's ability to support complex studies, such as chronic disease modeling, positions it as a critical asset for pharmaceutical companies aiming to accelerate breakthroughs and reduce clinical risks. As the industry shifts towards NAMs, PhysioMimix Core ensures researchers remain at the forefront of innovation, potentially leading to faster and more accurate drug development outcomes.
What's Next?
With the launch of PhysioMimix Core, CN Bio is poised to influence the future of drug development methodologies. Researchers and pharmaceutical companies are likely to adopt this system to enhance their experimental capabilities and improve the precision of their studies. As the field continues to evolve, CN Bio's collaboration with regulators will be crucial in anticipating and adapting to new legislative directions. The company's focus on providing a future-proof system suggests ongoing updates and enhancements to meet emerging research needs. The success of PhysioMimix Core could lead to broader acceptance and integration of OOC systems in drug development pipelines, potentially transforming industry standards.
AI Generated Content
Do you find this article useful?
